DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Adrenocortical carcinoma; Cholangiocarcinoma; Choriocarcinoma; Endometrial cancer; Fallopian tube cancer; Germ cell and embryonal neoplasms; Neuroendocrine tumours; Ovarian cancer; Seminoma; Squamous cell cancer; Teratoma
- Focus Therapeutic Use
- Acronyms DART
- 16 Nov 2017 Planned number of patients changed from 334 to 707.
- 18 Jan 2017 Status changed from not yet recruiting to recruiting.
- 27 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 1 Jun 2017.